ENTEROSTATIN, HUMAN manufacturers
- Enterostatin
-
- $0.00 / 10mg
-
2021-09-17
- CAS:117830-79-2
- Min. Order: 1mg
- Purity: 99%
- Supply Ability: 10KG
- ENTEROSTATIN, HUMAN
-
- $1.00 / 1g
-
2020-03-06
- CAS:117830-79-2
- Min. Order: 1g
- Purity: ≥98%
- Supply Ability: g/kg/Ton
|
| | ENTEROSTATIN, HUMAN Basic information |
| | ENTEROSTATIN, HUMAN Chemical Properties |
| density | 1.54±0.1 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | Soluble to 0.70 mg/ml in sterile water | | pka | 3.60±0.21(Predicted) | | form | Lyophilized solid. | | color | White to off-white |
| | ENTEROSTATIN, HUMAN Usage And Synthesis |
| Definition | ChEBI: APGPR Enterostatin is a peptide. | | Biological Activity | Enterostatin are pentapeptides that reduce fat intake. | | in vitro | In the perfused ratpancreas, Enterostatin, at 100 mM, inhibits the insulin response to 9 mM glucose (by 70%), 0.1 mM tolbutamide (by 40%), and 5 mM arginine (by 70%). | | in vivo | Chronically, enterostatin reduces fat intake, bodyweight, and body fat. This response may involve multiple metabolic effects of enterostatin, which include a reduction of insulin secretion, an increase in sympathetic drive to brown adipose tissue, and the stimulation of adrenal corticosteroid secretion. Enterostatin enhances memory consolidation after central or oral administration at a dose of 10 nmol/mouse or 300 mg/kg, respectively, in a step-through type passive avoidance test in mice. A dose of 38 nmol of enterostatin gives a significant inhibition of high-fat food intake, while at a higher dose of 76 nmol the inhibiting effect is lost. During the first hour, after injection of enterostatin, there is even a slight increase in food intake. | | target | | Human Endogenous Metabolite < span> | |
| | ENTEROSTATIN, HUMAN Preparation Products And Raw materials |
|